<div id="readability-page-1"><ul><li>5 medical stocks growing earnings by triple digits</li></ul><p>argenx SE (NASDAQ:ARGX - Free Report) -  William Blair issued their Q4 2026 earnings estimates for shares of argenx  in a report issued on  Monday, March 17th. William Blair analyst M. Minter anticipates that the company will earn $7.29 per share for the quarter. William Blair  has a &#34;Outperform&#34; rating on the stock. The consensus estimate for argenx's current full-year earnings is $3.13 per share.</p><p>Other research analysts also recently issued reports about the stock. Evercore ISI upped their target price on shares of argenx from $675.00 to $706.00 and gave the company an &#34;outperform&#34; rating in a research report on Thursday, November 21st. Citigroup  reiterated an &#34;outperform&#34; rating on shares of argenx in a research report on Friday, February 28th. Robert W. Baird increased their price target on shares of argenx from $650.00 to $680.00 and gave the company a &#34;neutral&#34; rating in a research report on Tuesday, March 4th. Truist Financial  reiterated a &#34;buy&#34; rating and issued a $700.00 price target (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Finally, Wells Fargo &amp; Company increased their target price on argenx from $723.00 to $741.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, nineteen have assigned  a buy rating and one  has issued  a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $687.00.</p><ul><li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li></ul><p><b>Check Out Our Latest Research Report on ARGX</b></p><h2>argenx Trading Up 1.5 %</h2><p>argenx stock opened at $614.19 on Tuesday. argenx has a 1 year low of $349.86 and a 1 year high of $678.21. The company has a market cap of $37.32 billion, a PE ratio of -697.94 and a beta of 0.59. The company's 50-day moving average is $637.58 and its two-hundred day moving average is $597.56. </p><p>argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. </p><h2>Institutional Investors Weigh In On argenx</h2><p>Several hedge funds have recently added to or reduced their stakes in the business. Lansforsakringar Fondforvaltning AB publ acquired a new stake in  argenx during the 4th quarter valued at $267,000.  Brucke Financial Inc. acquired a new position in  argenx in the fourth quarter valued at about $412,000.  Mackenzie Financial Corp raised its stake in  argenx by 81.4% in the fourth quarter. Mackenzie Financial Corp now owns 4,449 shares of the company's stock valued at $2,736,000 after purchasing an additional 1,996 shares in the last quarter.  GF Fund Management CO. LTD. acquired a new position in  argenx in the fourth quarter valued at about $416,000.  Finally, Vise Technologies Inc. raised its stake in  argenx by 6.8% in the fourth quarter. Vise Technologies Inc. now owns 799 shares of the company's stock valued at $491,000 after purchasing an additional 51 shares in the last quarter. Institutional investors and hedge funds own  60.32% of the company's stock. </p><h2>argenx Company Profile</h2> (Get Free Report)<p>argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.</p><h2>Read More</h2><ul><li>Five stocks we like better than argenx</li><li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li><li>CrowdStrike Stock Attracts Congressional Buyers—Time to Invest?</li><li>How to Use the MarketBeat Stock Screener </li><li>ARK Innovation Fund Bets Big on Bitcoin—Will It Pay Off?</li><li>What is Insider Trading? What You Can Learn from Insider Trading</li><li>Can TikTok Stock Picks Really Make You Rich?</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJHWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in argenx Right Now?</h2><p>Before you consider argenx, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.</p><p>While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARGX

<p>William Blair has issued Q4 2026 earnings estimates for argenx SE (NASDAQ:ARGX), predicting earnings of $7.29 per share. The current full-year earnings consensus is $3.13 per share. Analysts have generally rated the stock positively, with target prices ranging from $675.00 to $741.00. The stock opened at $614.19, with a market cap of $37.32 billion. Argenx reported $1.58 EPS for the last quarter, exceeding estimates, and has a negative net margin of 2.11%. Institutional investors hold 60.32% of the company's stock.</p>

Q4 Earnings Forecast for argenx Issued By William Blair